-transparent.png){kind=logo}
To determine the reaction of the gastric mucosa to HP 549 (isoxepac) an oxo-dibenz-oxepine derivative of acetic acid and new non-steroidal antiphlogistic agent in comparison with standard drugs, 12 healthy volunteers received 3 g of Aspirin, 150 mg of indomethacin, or 600 mg of HP 549 (isoxepac) in a double-blind cross-over trial. Before and after each treatment period, all subjects underwent gastroscopy with biopsy of gastric mucosa. The subjects recorded complaints (side effects) before and after each treatment period. Aspirin produced significantly more gross mucosal changes at endoscopy. There was no significant difference between isoxepac and indomethacin. Both produced very few gastric mucosal changes and there were few subjective complaints.
L B Svendsen, and
O H Hansen, and
A Johansen
January 1959,
Canadian Medical Association journal,
L B Svendsen, and
O H Hansen, and
A Johansen
February 1977,
Metabolism: clinical and experimental,
L B Svendsen, and
O H Hansen, and
A Johansen
April 1968,
Gastroenterology,
L B Svendsen, and
O H Hansen, and
A Johansen
January 1973,
Arkhiv patologii,
L B Svendsen, and
O H Hansen, and
A Johansen
January 1987,
Cellular and molecular biology,
L B Svendsen, and
O H Hansen, and
A Johansen
May 1975,
Research communications in chemical pathology and pharmacology,
L B Svendsen, and
O H Hansen, and
A Johansen
May 1981,
British journal of clinical pharmacology,
L B Svendsen, and
O H Hansen, and
A Johansen
June 1977,
L'union medicale du Canada,
L B Svendsen, and
O H Hansen, and
A Johansen
January 1960,
Schweizerische medizinische Wochenschrift,
L B Svendsen, and
O H Hansen, and
A Johansen
June 1978,
The American journal of physiology,
